Loading...
NPI 1184201220 · Dallas, TX · Clinical Medical Laboratory
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Yellowstone Labs, LLC is a clinical medical laboratory provider located in Dallas, Texas. This profile covers 16 Medicare and 17 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Organization |
| Organization | Yellowstone Labs, LLC |
| Address | 4300 N Central Expy Ste 300 |
| City | Dallas |
| State | TX |
| ZIP | 75206 |
| Taxonomy | Clinical Medical Laboratory |
| NPI Enumerated | March 25, 2021 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicare | $35.4M |
| Medicaid | $227.7K |
YELLOWSTONE LABS, LLC presents as a high-throughput molecular diagnostic laboratory: its top-billing codes are dominated by amplified nucleic acid probe techniques and multiplex respiratory pathogen assays (examples include 87798, 87150, 87631, 87502). The code mix — heavy on broad infectious-agent testing and multiplex respiratory panels — indicates the operation is geared toward centralized, volume-based molecular testing rather than low-volume specialized anatomic pathology or point-of-care services.
Medicare revenue is highly concentrated: the top 3 Medicare codes by revenue account for 61.1% of the provider's total Medicare revenue, with 87798 reporting 419.8K claims and $14.3M revenue, 87150 reporting 121.1K claims and $4.1M revenue, and 87631 reporting 21.7K claims and $3M revenue. This concentration shows dependence on a small set of high-volume molecular assays to generate the bulk of its $35.4M Medicare receipts.
On Medicare competitive standing, the provider scores as a national leader for several assays: 87798 ranks #2 of 1319 providers (100th percentile; extreme outlier), 87150 ranks #3 of 190 providers (99th percentile; extreme outlier), and 87631 ranks #1 of 636 providers (100th percentile; extreme outlier). Multiple additional CPTs also rank at #1 or in the 100th-percentile band, signaling that YELLOWSTONE LABS is an outsized national player for many amplified-probe tests.
Medicaid volume is small relative to Medicare: lifetime Medicaid revenue is $227.7K versus $35.4M in Medicare, so the practice is effectively Medicare-dominant in scale. Although the same assay types appear in the Medicaid mix, Medicaid dollars represent a very small share of overall billing and would not materially change payer-concentration dynamics.
Within Medicaid the top 3 codes account for 55.5% of the provider's Medicaid revenue, led by 87798 at 6.9K claims and $89.3K revenue, followed by 87150 at 2.9K claims and $20.5K revenue, and 87631 at 3.1K claims and $18.3K revenue. State-level ranks for these codes are generally in the typical range (for example, 87798 ranks #30 of 243 in-state, 88th percentile), indicating the provider’s Medicaid activity is more ordinary within Texas even while its Medicare volumes are exceptional.
There is one notable Medicaid exception: 87634 (RSV) is ranked #11 of 151 in-state (93rd percentile; notably above typical state volume), suggesting somewhat stronger relative activity for RSV testing in the Medicaid population compared with the provider’s other Medicaid assays. This could reflect temporary demand drivers or a specific in-state contracting relationship for that particular respiratory assay.
The provider’s national outlier status on multiple Medicare codes (many listed as "extreme outlier" at or near the 100th percentile) implies substantial centralized processing capacity and/or wide sample sourcing across referral networks; examples include many rank #1 listings across respiratory, bacterial, and resistance marker assays. Such scale supports negotiating leverage for lab supplies and automation but also means revenue sensitivity to changes in reimbursement or test utilization for a narrow set of assays.
Operationally and from a tenure perspective, YELLOWSTONE LABS has an NPI enumerated 2021-03-25 (~5 years ago) and has achieved a large Medicare billing footprint in a relatively short window. The combination of brief tenure and unusually high national ranks on core molecular codes suggests rapid scaling focused on amplified-probe infectious testing, which is an important consideration for payer network planning and competitive benchmarking.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
16 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 87798 | The lab analyst performs a test for an infectious agent not specified in another code using an amplified nucleic acid probe technique. Use this code if you know the laboratory technique is amplified… | 419,780 | $30 | $14.3M |
| 87150 | The lab analyst performs an analysis using amplified DNA or RNA probe technique on a previously isolated and identified organism to categorize the organism more specifically, such as to the taxonomic… | 121,080 | $30 | $4.1M |
| 87631 | The lab analyst performs the technical steps to detect three to five types or subtypes of pathogens, such as adenovirus, influenza virus, coronavirus, metapneumovirus, parainfluenza virus,… | 21,700 | $140 | $3M |
| 87502 | The lab analyst performs a test to determine the presence of multiple types or subtypes of influenza virus through nucleic acid detection using multiplex amplified probe technique and possibly… | 21,700 | $90 | $2M |
| 87481 | The lab analyst performs a test for Candida species using amplified nucleic acid probe technique. | 48,100 | $30 | $1.6M |
| 87634 | The lab analyst performs a test for respiratory syncytial virus (RSV) antigen detection using amplified nucleic acid probe technique. | 21,700 | $70 | $1.5M |
| 87529 | The lab analyst performs a test for Herpes simplex virus, HSV, using amplified nucleic acid probe technique. HSV causes clusters of blisters, or vesicles, on different parts of the body and spreads… | 43,390 | $30 | $1.5M |
| 87652 | The lab analyst performs a test to quantify infection with Streptococcus, group A, using nucleic acid probe technique. | 23,820 | $40 | $976.7K |
| 87500 | The lab analyst performs a test for vancomycin resistance in an infectious organism’s nucleic acid using amplified probe technique. VRE, vancomycin resistant enterococcus, is the most common organism… | 23,810 | $30 | $809.4K |
| 87641 | The lab analyst performs a test for methicillin–resistant Staphylococcus aureus (MRSA) using an amplified nucleic acid probe technique. | 23,740 | $30 | $807K |
Showing 1–10 of 16
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 16 CPT/HCPCS codes.
View: State1 / 2
Full comparison — all codes billed, vs. state median
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
17 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 87798 | The lab analyst performs a test for an infectious agent not specified in another code using an amplified nucleic acid probe technique. Use this code if you know the laboratory technique is amplified… | 6,870 | $10 | $89.3K |
| 87150 | The lab analyst performs an analysis using amplified DNA or RNA probe technique on a previously isolated and identified organism to categorize the organism more specifically, such as to the taxonomic… | 2,930 | $10 | $20.5K |
| 87631 | The lab analyst performs the technical steps to detect three to five types or subtypes of pathogens, such as adenovirus, influenza virus, coronavirus, metapneumovirus, parainfluenza virus,… | 3,050 | $10 | $18.3K |
| 87502 | The lab analyst performs a test to determine the presence of multiple types or subtypes of influenza virus through nucleic acid detection using multiplex amplified probe technique and possibly… | 3,080 | $10 | $15.4K |
| 87529 | The lab analyst performs a test for Herpes simplex virus, HSV, using amplified nucleic acid probe technique. HSV causes clusters of blisters, or vesicles, on different parts of the body and spreads… | 3,090 | $1 | $12.4K |
| 87634 | The lab analyst performs a test for respiratory syncytial virus (RSV) antigen detection using amplified nucleic acid probe technique. | 3,080 | $1 | $12.3K |
| 87481 | The lab analyst performs a test for Candida species using amplified nucleic acid probe technique. | 3,740 | $1 | $11.2K |
| 87652 | The lab analyst performs a test to quantify infection with Streptococcus, group A, using nucleic acid probe technique. | 3,610 | $1 | $7.2K |
| 87640 | The lab analyst performs the technical lab test to look for Staphylococcus aureus nucleic acid using an amplified probe technique. | 3,140 | $1 | $6.3K |
| 87498 | A lab tests a patient’s specimen to provide a definitive diagnosis of meningitis by amplified probe technique. | 3,080 | $1 | $6.2K |
Showing 1–10 of 17
How this provider's Medicaid billing volume and revenue compare to other Texas providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. Texas median
17 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| 87798 | The lab analyst performs a test for an infectious agent not specified in another code using an amplified nucleic acid probe technique. Use this code if you know the laboratory technique is amplified… | 30 | 240 | 420 | $30 | $296.8K |
| 87631 | The lab analyst performs the technical steps to detect three to five types or subtypes of pathogens, such as adenovirus, influenza virus, coronavirus, metapneumovirus, parainfluenza virus,… | 19 | 140 | 180 | $60 | $215.9K |
| 87502 | The lab analyst performs a test to determine the presence of multiple types or subtypes of influenza virus through nucleic acid detection using multiplex amplified probe technique and possibly… | 48 | 350 | 230 | $70 | $120.3K |
| 87481 | The lab analyst performs a test for Candida species using amplified nucleic acid probe technique. | 31 | 170 | 440 | $20 | $93.6K |
| 87651 | The lab analyst performs a test for the bacteria Streptococcus, group A, using amplified nucleic acid probe technique. Strep A commonly causes acute pharyngitis, or strep throat. | 67 | 420 | 340 | $20 | $73.4K |
| 87150 | The lab analyst performs an analysis using amplified DNA or RNA probe technique on a previously isolated and identified organism to categorize the organism more specifically, such as to the taxonomic… | 6 | 50 | 380 | $20 | $63.4K |
| 87653 | The lab analyst performs a test for Streptococcus, group B, using amplified nucleic acid probe technique. The amplified probe provides a rapid means to assess colonization by Streptococcus, group B,… | 115 | 140 | 330 | $10 | $62.3K |
| 87529 | The lab analyst performs a test for Herpes simplex virus, HSV, using amplified nucleic acid probe technique. HSV causes clusters of blisters, or vesicles, on different parts of the body and spreads… | 11 | 60 | 310 | $20 | $58.9K |
| 87581 | The lab analyst performs a test for Mycoplasma pneumonia, a bacteria, using amplified nucleic acid probe technique. | 14 | 140 | 220 | $10 | $52.6K |
| 87640 | The lab analyst performs the technical lab test to look for Staphylococcus aureus nucleic acid using an amplified probe technique. | 20 | 130 | 330 | $10 | $51.7K |
Showing 1–10 of 17
Other providers in the same ZIP code as Yellowstone Labs, LLC, ranked by combined Medicare and Medicaid revenue.
| Provider | State | Taxonomy | Medicare Revenue | Medicaid Revenue |
|---|---|---|---|---|
| Ariel Amana Healthcare Inc | TX | Home Health Agency | $0 | $13.9M |
| Coronado Labs LLC | TX | Clinical Medical Laboratory | $4.4M | $34.2K |
| Steven Herzog | TX | Neurology Physician | $1.5M | $0 |
| Alan Martin | TX | Neurology Physician | $990.6K | $0 |
| Donald Wurzburg | TX | Interventional Cardiology Physician | $805.3K | $0 |
| Manuel Cruz | TX | Interventional Cardiology Physician | $434.3K | $0 |
| Qingqing Xia | TX | Psychologist | $396.6K | $0 |
| Kalima Charway | TX | Clinical Psychologist | $377.3K | $0 |
| Nicole Davis | TX | Clinical Psychologist | $358K | $0 |
| Nathan Walters | TX | Physical Medicine & Rehabilitation Physician | $350.5K | $0 |
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.